Biggest News Aggregation in the World
📰 Prospectus Rules News

Page 10 - Prospectus Rules News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Prospectus Rules. Real-time updates on events, politics, business and more.

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Aelis Farma, a biopharmaceutical company developing a new generation of drugs for brain diseases, announces the success of its initial public offering and raises approximately €25 million on Euronext Paris

16.02.2022 - Regulatory News: Aelis Farma (Paris: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases (the Company), announces today the successful completion of its initial public offering on ...
United States United Kingdom Bpifrance Financement Vincenzo Piazza Inserm Magendie Neurocentre Daelis Farma

Aelis Farma, a biopharmaceutical company developing a new generation of drugs for brain diseases, announces the success of its initial public offering and raises approximately €25 million on Euronext Paris

Capital increase of approximately €25 million, i.e. 100% of the initial objective, despite high market volatility Size of the transaction which may be increased to approximately €25.55 million
United States United Kingdom Bpifrance Financement Kostenloser Wertpapierhandel Nicolas Merigeau Vincenzo Piazza

Aelis Farma, a Biopharmaceutical Company Developing a New Generation of Drugs for Brain Diseases, Launches Its Initial Public Offering on the Regulated Market of Euronext Paris

02.02.2022 - Regulatory News: Not to be distributed, directly or indirectly, in the United States of America, Canada, Australia, Japan or South Africa. Aelis Farma, a clinical-stage biopharmaceutical company specializing in the development of treatments for ...
United States France General United Kingdom South Africa Comunidad Autonoma De Cataluna Vincenzo Piazza

Aelis Farma, a Biopharmaceutical Company Developing a New Generation of Drugs for Brain Diseases, Launches Its Initial Public Offering on the Regulated Market of Euronext Paris

Capital increase of €25 million, which may be increased to a maximum of approximately €33 million in the event the Extension Clause and the Over-Allotment Option are fully exercised Irrevocable
United States France General United Kingdom South Africa Comunidad Autonoma De Cataluna Kostenloser Wertpapierhandel

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science